Filipe Vicente dos Santos Bueno

Filipe Vicente dos Santos Bueno

Auto-generated profile, based on publicly available information

Filipe Vicente dos Santos Bueno

Pediatric Hematology-Oncology Program, Research Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Archives of Medical Research
Verified
Journal Article
Closed access
FAFrancianne Gomes Andrade
Francianne Gomes Andrade
ENElda Pereira Noronha
Elda Pereira Noronha
GBGisele Dallapicola Brisson
Gisele Dallapicola Brisson
FBFilipe dos Santos Vicente Bueno
Filipe dos Santos Vicente Bueno
ICIngrid Sardou Cezar
Ingrid Sardou Cezar
GZGustavo Zamperlini
Gustavo Zamperlini

31 October 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
LMLuísa Vieira Codeço Marques
Luísa Vieira Codeço Marques
ENElda Pereira Noronha
Elda Pereira Noronha
FAFrancianne Gomes Andrade
Francianne Gomes Andrade
FSFilipe Vicente dos Santos-Bueno
Filipe Vicente dos Santos-Bueno
MMMarcela B. Mansur
Marcela B. Mansur
MPMaria S. Pombo-De-Oliveira
Maria S. Pombo-De-Oliveira
CD44 is a glycoprotein expressed in leucocytes and a marker of leukemia-initiating cells, being shown to be important in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL). In this study, we have (i) identified the aberrant antigenic pattern of CD44 and its isoform CD44v6 in T-ALL; (ii) tested the association with different T-cell subtypes and genomic alterations; (iii) identified the impact of CD44 status in T-ALL outcome. Samples from 184 patients (123 T-ALL and 61 AML; <19 years) were analyzed throughout multiparametric flow cytometry. Mutations in N/KRAS, NOTCH1, FBXW7 as well as STIL-TAL1 and TLX3 rearrangements were detected using standard molecular techniques. CD44 expression was characterized in all T-ALL and AML cases. Compared with AML samples in which the median fluorescence intensity (MFI) was 79.1 (1–1272), T-ALL was relatively low, with MFI 43.2 (1.9–1239); CD44v6 expression was rarely found, MFI 1 (0.3-3.7). T-ALL immature subtypes (mCD3/CD1aneg) had a lower CD44 expression, MFI 57.5 (2.7–866.3), whereas mCD3/TCRγδpos cases had higher expressions, MFI 99.9 (16.4–866.3). NOTCH1mut and STIL-TAL1 were associated with low CD44 expression, whereas N/KRASmut and FBXW7mut cases had intermediate expression. In relation to clinical features, CD44 expression was associated with tumor infiltrations (p = 0.065). However, no association was found with initial treatment responses and overall survival prediction. Our results indicate that CD44 is aberrantly expressed in T-ALL being influenced by different genomic alterations. Unraveling this intricate mechanism is required to place CD44 as a therapeutic target in T-ALL.

30 November 2017 in ecancermedicalscience
Verified
Journal Article
Open access
MPMaria S. Pombo-De-Oliveira
Maria S. Pombo-De-Oliveira
FAFrancianne Gomes Andrade
Francianne Gomes Andrade
HAHeba Abdallah
Heba Abdallah
GBGisele Dallapicola Brisson
Gisele Dallapicola Brisson
FBFilipe Vicente dos Santos Bueno
Filipe Vicente dos Santos Bueno
ENElda Pereira Noronha
Elda Pereira Noronha
Acute myeloid leukaemia (AML) in early childhood is characterised by a high frequency of recurrent genomic aberrations associated with distinct myeloid subtypes, clinical outcomes and pathogenesis. Genomic instability is the first step of pathogenic mechanism in early childhood AML. A sum of adverse events is necessary to the development of infant AML (i-AML), which includes latency of biochemical-molecular and cellular effects. Inherited genetic susceptibility associated with exposures to biotransformation substances can modulate the risk of DNA damage and it is a very important piece in the pathogenic puzzle. In this review, we have aimed to explore the chain of events in the time-points of the natural history of i-AML, which includes maternal exposures during pregnancy, the speculations about the formation of somatic mutations during foetal life and the secondary genomic aberrations associated with i-AML. The modulation of risk conferred by xenobiotic metabolism´s genes variants is the bottom line of the pathogenic process. Since we have conducted observational and molecular investigations in early childhood leukaemia, the data focused here is based on Brazilian findings with summarised results of our experience with epidemiological and molecular studies in early-age leukaemia.

6 March 2022 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
DMDaniela Palheiro Mendes-de-Almeida
Daniela Palheiro Mendes-de-Almeida
FAFrancianne G. Andrade
Francianne G. Andrade
FSFilipe V. dos Santos-Bueno
Filipe V. dos Santos-Bueno
DFDayvison Freitas
Dayvison Freitas
SLSheila Lima
Sheila Lima
MPMaria S. Pombo-De-Oliveira
Maria S. Pombo-De-Oliveira
Haploinsufficiency of the hematopoietic transcription factor GATA2 is associated with a broad spectrum of diseases, including infection susceptibility and neoplasms. We aimed to investigate GATA2 variants in patients with non-tuberculous mycobacterial (NTM) and/or fungal infections (FI) without known immunodeficiencies. We performed GATA2 genotyping in patients with NTM and/or FI. Twenty-two patients were enrolled (seventeen FI, four NTM and one with both infections). The pathogenic variant NG_029334.1:g.16287C>T was found in one patient (4.5%) and two asymptomatic offsprings. We also found the likely-benign variant NG_029334.1:g.12080G>A (rs2335052), the benign variant NG_029334.1:g.16225C>T (rs11708606) and the variant of uncertain significance NG_029334.1:g.16201G>A (rs369850507) in 18.2%, 27.3%, and 4.5% of the cases, respectively. Malignant diseases were additionally diagnosed in six patients. Although detected in 45.4% of the patients, most GATA2 variants were benign or likely benign. Identifying a pathogenic variant was essential for driving both the patient's treatment and familial counseling. Pathogenic variants carriers should receive genetic counseling, subsequent infection prevention measures and malignancies surveillance. Additionally, case-control genotyping should be carried out in Brazil to investigate whether the observed variants may be associated with susceptibility to opportunistic infections and/or concurrent neoplasms.

31 March 2018 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
GBGisele Dallapicola Brisson
Gisele Dallapicola Brisson
BLBruno Lopes
Bruno Lopes
FAFrancianne Gomes Andrade
Francianne Gomes Andrade
FBFilipe Vicente dos Santos Bueno
Filipe Vicente dos Santos Bueno
ISIngrid Sardou-Cezar
Ingrid Sardou-Cezar
MPMaria S. Pombo-De-Oliveira
Maria S. Pombo-De-Oliveira

27 July 2020 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
DMDaniela Palheiro Mendes-de-Almeida
Daniela Palheiro Mendes-de-Almeida
FSFernando Sellos
Fernando Sellos
PMPatrícia G. Moura
Patrícia G. Moura
FSFilipe V. dos Santos-Bueno
Filipe V. dos Santos-Bueno
FAFrancianne G. Andrade
Francianne G. Andrade
MPMaria S. Pombo-De-Oliveira
Maria S. Pombo-De-Oliveira
(2020). Acute myeloid leukemia associated with a novel GATA2 mutation: a case report and the importance to identify GATA2 haplodeficiency. Leukemia & Lymphoma. Ahead of Print.